Adenoviral BCL-XL overexpression confers a stable competitive advantage during reconstitution in vivo. (A) Lethally irradiated heterozygous Ly5.1/Ly5.2 recipient mice were competitively transplanted with Ly5.1⁺ and Ly5.2⁺ LSK cells in a 50:50 ratio, which were pretreated as indicated in the table. (B–D) 10 d after transplantation, mice were sacrificed and analyzed. The dashed bar indicates the period of adenoviral gene expression. The Ly5.1⁺/ Ly5.2⁺ chimerism was determined by flow cytometry in splenic monocytes and granulocytes (B), double-negative (DN) and double-positive (DP) thymocytes (C), and BM-derived LSK cells (D). (E–G) Another set of mice was analyzed 16 wk after transplantation. The Ly5.1⁺/ Ly5.2⁺ chimerism was determined by flow cytometry in splenic monocytes and granulocytes (E), T lymphocytes (F), and BM-derived LSK cells (G). Bars represent means of n = 6–8 animals of two independent experiments ± SEM. Significant p-values (Wilcoxon test; Ly5.1⁺ vs. Ly5.2⁺): (B) Group 2: P = 0.05 in monocytes; (C) Group 1: P = 0.02 for DN4; Group 2: DN4 and DP, P = 0.03 for DN2 and DN3; Group 3: P = 0.05 for DN2, P = 0.03 for DN3, DN4, and DP; (D) Group 1: P = 0.03; Group 2: P = 0.05; (E) Group 3: P = 0.01 for monocytes; (F) Group 2+3: P = 0.02 for CD4⁺ T cells; P = 0.01 for CD8⁺ T cells; (G) Group 2: P = 0.02; group 3: P = 0.01.